Research of Resistance to Antiplatelet Agents and Development of Tailored Treatment Model for Patients With Coronary Artery Disease

The purpose of this study is to evaluate the prognosis of patients with resistance to antiplatelet agent and develop tailored treatment model for patients with coronary artery disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiovascular Diseases Arterial Occlusive Diseases Arteriosclerosis Coronary Artery Disease Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Asan Medical Center

Seoul, Songpa-Gu, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age >20
Patients with coronary artery disease
Patients with peripheral artery disease

Exclusion criteria

Renal dysfunction
Hepatic dysfunction
Major surgery planned within 1 year
Malignant tumor
History of gastrointestinal bleeding
low or high platelet count

Treatment and study plan

Primary outcomes

Major adverse event

Time frame: 2 year

Major adverse event : overall mortality, cardiovascular mortality, target vessel revascularization

Secondary outcomes

Biomarker

Time frame: 2 year

homocysteine, Lp(a), fibrinogen, PAI-1, NTpro-BNP, hs-CRP, matrix metalloproteinase-9, soluble CD40L, IL-6, serum amyloid A, AGE

Sponsors and collaborators

Lead sponsor

Young-Hak Kim, MD, PhD

Other

Registry information

Important dates

Study start: 2013
Primary completion: 2020
Study completion: 2020
First posted: Apr 23, 2014
Registry last updated: Mar 20, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed